GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Apraglutide

Company
VectivBio AG
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Apraglutide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07742735

    A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

    Not yet reported VectivBio AG 124 participants Est. completion 2029-10 94 sites Stand-alone
    Other conditions: Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
    View official trial listing →
  • Withdrawn NCT NCT03417765

    Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

    Not yet reported, Not yet reported GlyPharma Therapeutics Est. completion 2019-03-31
    Other conditions: Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Hodgkin's, Adult
    View official trial listing →
  • Completed NCT NCT04627025

    Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

    Not yet reported VectivBio AG 164 participants Est. completion 2024-02-22 68 sites Stand-alone
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT04699032

    Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

    Not yet reported VectivBio AG 16 participants Est. completion 2021-07-05 2 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT04964986

    Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)

    Not yet reported VectivBio AG 10 participants Est. completion 2023-06-06 2 sites Stand-alone
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT05018286

    Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

    Not yet reported VectivBio AG 158 participants Est. completion 2027-10-30 66 sites Stand-alone
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Terminated NCT NCT05415410

    Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

    Not yet reported VectivBio AG 31 participants Est. completion 2024-12-17 13 sites Stand-alone
    Other conditions: GVHD
    View official trial listing →
  • Completed NCT NCT05706623

    A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

    Not yet reported VectivBio AG 16 participants Est. completion 2023-04-04 2 sites Stand-alone
    Other conditions: Hepatic Impairment
    View official trial listing →
  • Completed NCT NCT05995704

    Evaluation of Apraglutide on Gastric Emptying

    Not yet reported VectivBio AG 42 participants Est. completion 2023-07-24 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT06002555

    Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation

    Not yet reported VectivBio AG 34 participants Est. completion 2023-09-22 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.